Smith Julie
Stoke Therapeutics, Inc. · Director
Julie Smith serves as a Director at Stoke Therapeutics, Inc., overseeing strategic initiatives within the healthcare sector. Her recent trading activity, tracked through SEC Form 4 filings, indicates a focus on sale transactions, primarily involving Exelixis Inc (EXEL) and Stoke Therapeutics (STOK). From August 15, 2024, to June 5, 2026, Smith reported 16 disclosures, with a notable sale of over $2.1 million in EXEL shares on February 28, 2025, highlighting her active engagement in the market.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $2M44.1k shares | SellFeb 18, 2026 | $44.50 | $55.65 | |
| $887k20k shares | SellFeb 18, 2026 | $44.30 | $55.65 |